Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Grace Therapeutics (Nasdaq: GRCE) announced CEO Prashant Kohli will present at TD Cowen’s 46th Annual Health Care Conference in Boston on March 4, 2026 at 10:30 AM ET. An archived replay will be available for 90 days, and the CEO will also take part in investor meetings.

According to the company, Grace is advancing GTx-104, a clinical-stage injectable nimodipine formulation for IV infusion targeting aneurysmal subarachnoid hemorrhage patients.

News Market Reaction – GRCE

-1.21%

1 alert

-1.21% News Effect

-$749K Valuation Impact

$61M Market Cap

0.4x Rel. Volume

On the day this news was published, GRCE declined 1.21%, reflecting a mild negative market reaction. This price movement removed approximately $749K from the company's valuation, bringing the market cap to $61M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 2–4, 2026 Company presentation time: 10:30 AM Eastern Time Webcast replay period: 90 days

3 metrics

Conference dates March 2–4, 2026 TD Cowen 46th Annual Health Care Conference schedule

Company presentation time 10:30 AM Eastern Time Grace Therapeutics presentation on March 4, 2026

Webcast replay period 90 days Archived replay availability following the event

Market Reality Check

Price: $3.76 Vol: Volume 96,916 is below th...

normal vol

$3.76 Last Close

Volume Volume 96,916 is below the 20-day average of 110,237 (relative volume 0.88x). normal

Technical Price at $4.12 is trading above the 200-day MA of $3.21 and 4.19% below the 52-week high of $4.30.

Peers on Argus

GRCE was up 2.49% while peers showed mixed moves: PSTV up 3.02%, ANVS up 12.13%,...

2 Up

GRCE was up 2.49% while peers showed mixed moves: PSTV up 3.02%, ANVS up 12.13%, and others like PEPG and VRCA slightly down. Momentum scanner flagged only two peers (PSTV, ANVS), so the move appeared more stock-specific than broad sector-driven.

Historical Context

5 past events · Latest: Feb 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 12	Earnings and NDA update	Positive	-1.7%	Q3 2026 results, NDA progress, and PDUFA date of April 23, 2026.
Nov 17	Investor conference	Positive	-2.0%	CEO presentation at Craig-Hallum Alpha Select investor conference.
Nov 13	Earnings and NDA acceptance	Positive	+2.3%	Q2 2026 results, NDA acceptance, patent extension to 2043.
Nov 11	Clinical presentation	Positive	+0.4%	Phase 3 STRIVE-ON trial abstract accepted for major neurology meeting.
Oct 23	Financing and NDA update	Positive	+1.9%	Raised ~$4.0M via warrant exercises after NDA acceptance for GTx-104.

Pattern Detected

Across recent updates – including NDA, clinical, financing, and conference news – GRCE showed 3 aligned and 2 divergent price reactions, indicating mixed but somewhat constructive responses to news.

Recent Company History

Over the last several months, Grace Therapeutics has focused on advancing GTx-104 toward potential approval. The FDA accepted the NDA and set a PDUFA target date of April 23, 2026, supported by Phase 3 STRIVE-ON safety data. The company narrowed its net loss to $2.3M and strengthened its balance sheet with warrant exercises raising about $4.0M. Prior news included positive clinical presentations and participation in investor conferences, positioning today’s conference announcement as part of ongoing outreach and pre-commercial preparation.

Market Pulse Summary

This announcement highlights Grace Therapeutics’ participation in a major healthcare investor confer...

Analysis

This announcement highlights Grace Therapeutics’ participation in a major healthcare investor conference, including a presentation on March 4, 2026 at 10:30 AM Eastern Time and additional one-on-one meetings. It fits into an ongoing pattern of investor outreach alongside progress on GTx-104, which has an FDA PDUFA date of April 23, 2026. Investors may focus on how management uses such events to discuss clinical data, regulatory timelines, cash resources, and commercialization planning for GTx-104.

Key Terms

nimodipine, iv infusion, aneurysmal subarachnoid hemorrhage

3 terms

nimodipine medical

"a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion"

Nimodipine is a medicine that helps keep small arteries in the brain open after bleeding in the brain, improving blood flow and lowering the risk of further brain damage. For investors, nimodipine matters because regulatory approvals, clinical trial results, patent status, and safety records determine whether a company can sell it widely or add it to a product line, which affects revenue and risk—think of it as a key product in a company's medical toolbox.

iv infusion medical

"novel, injectable formulation of nimodipine being developed for IV infusion to address"

An IV infusion is the delivery of fluids, medicines or nutrients directly into a vein through a small tube over a set period, like a controlled fuel line topping up a machine. For investors, IV infusion matters because many approved therapies and some high-value treatments require this route of administration, affecting how treatments are delivered, the costs and capacity of clinics or hospitals, reimbursement and the recurring revenue potential of providers.

aneurysmal subarachnoid hemorrhage medical

"needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that"

Aneurysmal subarachnoid hemorrhage is bleeding into the thin space surrounding the brain caused when a weakened blood vessel balloon (an aneurysm) bursts. Like a burst pipe leaking into a narrow hallway, it can cause sudden, severe damage and often requires urgent surgery or devices and long hospital care. For investors, its frequency, treatment options, and outcomes influence demand for medical devices, drugs, hospital services, clinical trial results and health-care spending.

AI-generated analysis. Not financial advice.

PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in TD Cowen’s 46^th Annual Health Care Conference, to be held March 2-4, 2026 in Boston, MA.

Mr. Kohli’s presentation is schedule for March 4, 2026 at 10:30 AM Eastern Time. To register for the webcast, click here. An archived replay will be available for 90 days following the event.

In addition, Mr. Kohli will participate in one-on-one and group investor meetings.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is a relatively uncommon type of stroke (aSAH) that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.

About GTx-104

GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to oral nimodipine.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutic’s lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with over 40 granted and pending patents. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull.

For more information, please visit: www.gracetx.com. 

For more information, please contact:

Grace Therapeutics Contact:

Prashant Kohli
Chief Executive Officer
Tel: 609-322-1602
Email: info@gracetx.com
www.gracetx.com

Investor Relations:

LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: mmoyer@lifesciadvisors.com

FAQ

When will Grace Therapeutics (GRCE) present at the TD Cowen 46th Annual Health Care Conference?

Grace Therapeutics will present on March 4, 2026 at 10:30 AM ET. According to the company, CEO Prashant Kohli is the scheduled presenter and will discuss company developments and engage with investors during the conference.

How can investors access the Grace Therapeutics (GRCE) webcast for the TD Cowen conference?

Investors can register to access the live webcast via the company’s registration link. According to the company, an archived replay will be available for 90 days after the event for later viewing.

What will Grace Therapeutics (GRCE) likely discuss about GTx-104 at the March 4, 2026 presentation?

The presentation will cover company progress on GTx-104, a clinical-stage injectable nimodipine for IV infusion. According to the company, GTx-104 targets unmet needs in aneurysmal subarachnoid hemorrhage patients and is in late-stage development.

Will Grace Therapeutics (GRCE) hold investor meetings at the TD Cowen conference?

Yes, the CEO will participate in one-on-one and group investor meetings during the conference. According to the company, these meetings accompany the March 4 presentation to engage current and potential investors directly.

How long will the Grace Therapeutics (GRCE) conference replay remain available after TD Cowen?

The replay will remain available for 90 days following the event. According to the company, investors unable to join live can view the archived presentation during that 90-day window.